Table 3.
Open in new tab

Summary of activity for the seven isolates tested in inhaled amikacin and intravenous meropenem combination therapy

Isolate numberaAUBC over 24 hb
control groupamikacin monotherapy (inhaled)meropenem monotherapy (intravenous)combination therapyP
KP 376195.2 ± 0.346.4 ± 0.1e,g156.7 ± 0.1e,f49.0 ± 0.1f,g<0.001c
KP 375199.8 ± 1.362.2 ± 2.9e,g161.7 ± 0.7e,f50.9 ± 0.4f,g<0.001c
KP 352195.4NTNT51.1 ± 0.3NT
KP 508197.1 ± 0.9190.5 ± 0.1e,g143.7 ± 1.1e,f114.7 ± 4.9f,g<0.001c
PSA 1504186.2 ± 1.246.4 ± 1.5e86.2 ± 2.4e,f43.1 ± 0.0f<0.001c
PSA 1544188.2 ± 3.085.9 ± 4.8e185.8 ± 1.3e,f74.9 ± 15.8f0.002c
PSA 1547182.9 ± 0.5180.5 ± 0.4NT179.5 ± 0.60.189d
Isolate numberaAUBC over 24 hb
control groupamikacin monotherapy (inhaled)meropenem monotherapy (intravenous)combination therapyP
KP 376195.2 ± 0.346.4 ± 0.1e,g156.7 ± 0.1e,f49.0 ± 0.1f,g<0.001c
KP 375199.8 ± 1.362.2 ± 2.9e,g161.7 ± 0.7e,f50.9 ± 0.4f,g<0.001c
KP 352195.4NTNT51.1 ± 0.3NT
KP 508197.1 ± 0.9190.5 ± 0.1e,g143.7 ± 1.1e,f114.7 ± 4.9f,g<0.001c
PSA 1504186.2 ± 1.246.4 ± 1.5e86.2 ± 2.4e,f43.1 ± 0.0f<0.001c
PSA 1544188.2 ± 3.085.9 ± 4.8e185.8 ± 1.3e,f74.9 ± 15.8f0.002c
PSA 1547182.9 ± 0.5180.5 ± 0.4NT179.5 ± 0.60.189d

aKP, K. pneumoniae; PSA, P. aeruginosa.

bExpressed as log10 cfu·h/mL over 24 h; the value for each isolate is the mean ± SD of two independent time–kill experiments for treatment groups and two or three experiments for control groups.

cOne-way ANOVA test among three treatment groups; NT, not tested.

dt-test between combination therapy and control group; two-tailed P value.

eP < 0.05 between amikacin monotherapy and meropenem monotherapy.

fP < 0.05 between meropenem monotherapy and combination therapy.

gP < 0.05 between amikacin monotherapy and combination therapy.

Table 3.
Open in new tab

Summary of activity for the seven isolates tested in inhaled amikacin and intravenous meropenem combination therapy

Isolate numberaAUBC over 24 hb
control groupamikacin monotherapy (inhaled)meropenem monotherapy (intravenous)combination therapyP
KP 376195.2 ± 0.346.4 ± 0.1e,g156.7 ± 0.1e,f49.0 ± 0.1f,g<0.001c
KP 375199.8 ± 1.362.2 ± 2.9e,g161.7 ± 0.7e,f50.9 ± 0.4f,g<0.001c
KP 352195.4NTNT51.1 ± 0.3NT
KP 508197.1 ± 0.9190.5 ± 0.1e,g143.7 ± 1.1e,f114.7 ± 4.9f,g<0.001c
PSA 1504186.2 ± 1.246.4 ± 1.5e86.2 ± 2.4e,f43.1 ± 0.0f<0.001c
PSA 1544188.2 ± 3.085.9 ± 4.8e185.8 ± 1.3e,f74.9 ± 15.8f0.002c
PSA 1547182.9 ± 0.5180.5 ± 0.4NT179.5 ± 0.60.189d
Isolate numberaAUBC over 24 hb
control groupamikacin monotherapy (inhaled)meropenem monotherapy (intravenous)combination therapyP
KP 376195.2 ± 0.346.4 ± 0.1e,g156.7 ± 0.1e,f49.0 ± 0.1f,g<0.001c
KP 375199.8 ± 1.362.2 ± 2.9e,g161.7 ± 0.7e,f50.9 ± 0.4f,g<0.001c
KP 352195.4NTNT51.1 ± 0.3NT
KP 508197.1 ± 0.9190.5 ± 0.1e,g143.7 ± 1.1e,f114.7 ± 4.9f,g<0.001c
PSA 1504186.2 ± 1.246.4 ± 1.5e86.2 ± 2.4e,f43.1 ± 0.0f<0.001c
PSA 1544188.2 ± 3.085.9 ± 4.8e185.8 ± 1.3e,f74.9 ± 15.8f0.002c
PSA 1547182.9 ± 0.5180.5 ± 0.4NT179.5 ± 0.60.189d

aKP, K. pneumoniae; PSA, P. aeruginosa.

bExpressed as log10 cfu·h/mL over 24 h; the value for each isolate is the mean ± SD of two independent time–kill experiments for treatment groups and two or three experiments for control groups.

cOne-way ANOVA test among three treatment groups; NT, not tested.

dt-test between combination therapy and control group; two-tailed P value.

eP < 0.05 between amikacin monotherapy and meropenem monotherapy.

fP < 0.05 between meropenem monotherapy and combination therapy.

gP < 0.05 between amikacin monotherapy and combination therapy.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close